Clinical trial · Observational
Recurrence of Hepatocellular Carcinoma
Risk Factors for Recurrence of Hepatocellular Carcinoma After Radiofrequency Ablation
NCT01520779CI-TRIAL-00012323completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
analysis of the risk factors of intra-hepatic distant recurrence (IDR) of hepatocellular carcinoma within 1 year after radiofrequency ablation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Patients with recurrence
- description
- Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
- label
- Patients with no recurrence
- description
- Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
Primary outcomes (1)
- measure
- Recurrence of hepatocellular carcinoma
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Proved diagnosis of HCC according to AASLD practice guidelines (Bruix and Sherman, 2005). 2. Patients underwent RFA for HCC with BCLC (The Barcelona-Clinic- Liver-Cancer staging system) stage A (Bruix and Sherman, 2005) with no eligibility or ability to do transplantation or resection. 3. Patients should be followed-up for more than 12 months to exclude early recurrence i.e. recurrence within 1 year. 4. Patients with INR \< 1.5 or prothrombin concentration \> 50%. 5. Platelet count \> 50000 cell/mm3. Exclusion Criteria: 1. Presence of extra-hepatic metastasis or gross vascular invasion. 2. Child class C patients. 3. Follow up period of less than 12 months.
References
Publications (0)
Data not yet available
No reference posted for this study.